WCM-Rutgers NJMS CTU Supplement for COVID Testing

WCM-Rutgers NJMS CTU 针对新冠病毒检测的补充

• 批准号: 10166397
• 负责人: ROY M. GULICK
• 金额: $ 30万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-16 至 2021-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10166397
• 关键词: AIDS clinical trial group; Acquired Immunodeficiency Syndrome; Address; Administrative Supplement; Adult Respiratory Distress Syndrome; Affect; Area; COVID-19; COVID-19 pandemic; Clinical; Clinical Trials; Clinical Trials Network; Clinical Trials Unit; Communities; Community Healthcare; Coronavirus; Enrollment; Ensure; Funding; Future; HIV prevention trials network; Health Personnel; Individual; Infection; Laboratories; Lesbian Gay Bisexual Transgender Queer; Location; Minority; New Jersey; Research Institute; Services; Severe Acute Respiratory Syndrome; Site; Testing; United States; Work; clinical research site; cohort; coronavirus disease; high risk population; infection rate; interest; medical schools; named group; pandemic disease; programs; public health research

ABSTRACT The Rutgers New Jersey Medical School (NJMS) Clinical Research Site (CRS) 31786 is requesting $300,000 in funding to help support Severe Acute Respiratory Distress Syndrome Coronavirus-2 (SARS-CoV-2) testing. The CRS is part of the Weill Cornell-Rutgers NJMS Clinical Trials Unit and has been a site for two Division of AIDS (DAIDS) funded clinical trials networks: AIDS Clinical Trials Group (ACTG) and HIV Prevention Trials Network (HPTN) for fifteen years. The program plans to provide SARS-CoV-2 testing by leveraging its existing relationships with the local community and partnering with the clinical laboratory located at Public Health Research Institute (PHRI), also a Rutgers facility to perform SARS-CoV-2 testing using the Cepheid testing platform. The Cepheid COVID-19 testing platform has been developed at PHRI with Cepheid and is one of the most sensitive tests currently available to detect SARS-Co-V 2 infection. We will provide SARS-CoV-2 testing at the CRS, in an adjacent building and on a mobile van. These testing locations are well-known and easily accessible to the community, healthcare workers and other high-risk groups. We will also attempt to ensure that special populations such as minorities and the LGBTQ community have access to the test. Finally, this will help the CRS further strengthen its relationship with the community and allow the unit to provide an essential service to this hard-hit community. If funded, this project will allow us to rapidly increase the availability of SARS CoV-2 testing and help contribute to the urgent need for additional COVID testing in an underserved community located near the epicenter of the COVID-19 pandemic in the United States.

抽象的 罗格斯新泽西医学院 (NJMS) 临床研究中心 (CRS) 31786 是 请求 300,000 美元的资金来帮助支持严重急性呼吸窘迫综合症 冠状病毒 2 (SARS-CoV-2) 测试。 CRS 是威尔康奈尔-罗格斯大学 NJMS 的一部分 临床试验单位，一直是艾滋病司 (DAIDS) 资助的两个临床试验的场所 网络：艾滋病临床试验组 (ACTG) 和艾滋病毒预防试验网络 (HPTN) 十五年。 该计划计划利用其现有关系提供 SARS-CoV-2 检测 当地社区并与公共卫生部门的临床实验室合作 研究所 (PHRI)，也是罗格斯大学的一个设施，使用 造父变星测试平台。 Cepheid COVID-19 测试平台由 PHRI 开发 Cepheid 是目前可用于检测 SARS-Co-V 2 的最灵敏的测试之一 感染。 我们将在 CRS、邻近的建筑物和移动货车上提供 SARS-CoV-2 检测。 这些检测地点是众所周知的，并且社区、医疗保健机构可以轻松访问这些检测地点 工人和其他高危人群。我们还将努力确保特殊人群，例如 因为少数族裔和 LGBTQ 群体可以参加该测试。最后，这将有助于 CRS 进一步加强与社区的关系，使该单位能够提供必要的 为这个受灾严重的社区提供服务。 如果获得资助，该项目将使我们能够迅速提高 SARS CoV-2 检测和检测的可用性 帮助满足服务不足的社区对额外新冠病毒检测的迫切需求 位于美国 COVID-19 大流行的震中附近。